Dateline – November 17, 2025 | Bengaluru, India In a significant development for India’s pharmaceutical ecosystem, AstraZeneca Pharma India Limited and Sun Pharmaceutical Industries Limited have announced an exclusive partnership to broaden access to Sodium Zirconium Cyclosilicate (SZC), a modern therapy for hyperkalaemia, a potentially life-threatening electrolyte disorder. AstraZeneca will market the therapy under Lokelma®, while Sun Pharma will promote and distribute the product under Gimliand®, combining scientific leadership with commercial scale to reach patients across India. This collaboration aims to address the rising clinical burden of elevated potassium levels in patients living with chronic kidney disease (CKD) and heart failure, offering a new standard of care for a condition still associated with high mortality in the country.
Science Significance
The partnership brings renewed attention to hyperkalaemia, a condition that can arise in up to 50% of CKD patients and 42% of chronic heart failure patients, making it a substantial biomedical challenge. Sodium Zirconium Cyclosilicate, a highly selective potassium binder, acts rapidly within the gastrointestinal tract to remove excess potassium, making it scientifically valuable for stabilizing patients who are otherwise at risk of arrhythmias, emergency interventions, and treatment discontinuation. The therapy enables sustained potassium control that supports long-term disease management. Its precision mechanism, predictable onset, and favorable tolerability profile make SZC an important advancement in electrolyte pharmacotherapy, particularly in India where mortality related to hyperkalaemia still stands at 22.2%.
Regulatory Significance
Advertisement
AstraZeneca retains intellectual property rights, marketing authorization, and import licensing for SZC in India, ensuring stringent regulatory oversight aligned with global safety and efficacy standards. The collaboration indicates regulatory readiness for innovative agents addressing cardiorenal comorbidities. By expanding distribution through Sun Pharma, the therapy is poised for smoother regulatory-compliant penetration into diverse healthcare settings. The partnership also highlights the evolving Indian regulatory environment’s support for advanced therapies targeting high-burden non-communicable diseases. This alignment strengthens India’s pathway for future electrolyte, nephrology, and cardiovascular therapeutics while ensuring compliance with national drug regulations.
Business Significance
This alliance is strategically crucial for both companies. For AstraZeneca, it reinforces its commitment to innovative, life-changing medicines while leveraging Sun Pharma’s extensive reach across India’s healthcare networks. For Sun Pharma, India’s largest pharmaceutical company, the agreement expands its specialty portfolio with a globally recognized therapy. SZC’s market potential is substantial due to India’s high prevalence of CKD, hypertension, and heart failure, all of which elevate hyperkalaemia risk. With dual-brand strategy—Lokelma® and Gimliand®—the partnership is positioned to capture strong market penetration in tertiary hospitals, nephrology clinics, and cardiology centers. The collaboration sets a precedent for science-driven commercial partnerships aimed at accelerating access to advanced therapies in emerging markets.
Patients’ Significance
For Indian patients, the partnership represents a major step toward timely and reliable access to a therapy that can be lifesaving. Hyperkalaemia often limits the use of essential medications like RAAS inhibitors used for heart failure and CKD, forcing doctors to discontinue optimal therapy. SZC restores the possibility of continuing guideline-recommended treatments, improving both survival outcomes and quality of life. The partnership’s expanded distribution network ensures broader availability, particularly for patients in underserved regions. By improving disease stability and reducing emergency hospitalizations, the therapy offers meaningful clinical and economic relief to patients and caregivers alike.
Policy Significance
This collaboration aligns with national priorities targeting non-communicable diseases, which continue to impose significant healthcare burdens. Improved access to modern treatments supports India’s long-term health policy objectives of reducing mortality from cardiovascular and renal conditions. Furthermore, the partnership underscores the importance of public-private alignment in delivering innovative specialty medicines, ultimately supporting systemic reforms aimed at expanding treatment availability, strengthening chronic disease management, and optimizing therapeutic standards within nephrology and cardiology care pathways.
The AstraZeneca–Sun Pharma partnership marks a pivotal moment for India’s management of hyperkalaemia, combining scientific innovation with deep commercial reach to improve patient outcomes across the nation. With SZC set to become more widely accessible, India is better positioned to address the growing burden of cardiorenal diseases while moving toward stronger, more resilient chronic disease care. This strategic alliance stands out as a model for collaborative advancement in the pharmaceutical sector, driving value across science, regulation, business, and public health.
Source: AstraZeneca Pharma India Limited press release
